Literature DB >> 26045118

Doppler ultrasound measurement of resistance index in the diagnosis of prostate cancer.

Wei Huang1, Son Cen1, Xin-Li Kang1, Wei Fu Wang1, Yang Wang1, Xiang Chen2.   

Abstract

Prostate cancer (PCa) remains the second leading cause of cancer diagnosis worldwide. Early diagnosis and treatment of PCa is critical since the long-term prognosis is excellent in patients with tumors confined to the prostate gland. The current meta-analysis investigates the diagnostic value of resistive index (RI) measurement using color Doppler ultrasound in patients with PCa. Electronic literature databases were exhaustively searched for relevant studies published prior to May 31, 2014. Nine studies met our predetermined inclusion criteria for the present meta-analysis. The methodologic quality of the selected studies was independently assessed by 2 reviewers based on Quality Assessment of Diagnostic Accuracy Studies tool. Our meta-analysis results showed that RI values were significantly higher in malignant prostate tissues compared to normal prostate tissues (standardized mean difference [SMD] 0.42, 95% confidence interval [CI] 0.12~0.73, p = 0.007) and benign prostate tissues (SMD 0.41, 95% CI 0.26~0.56, p<0.001). Subgroup analysis based on the diagnostic instruments used revealed that RI values were accurate in diagnosis of PCa when compared between malignant tissue vs normal tissue and malignant tissue vs benign tissue (all p<0.05). Taken together, our findings support the potential clinical applications of RI values in diagnosis of PCa.

Entities:  

Mesh:

Year:  2015        PMID: 26045118     DOI: 10.5301/tj.5000309

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916            Impact factor:   2.098


  1 in total

1.  Clinical value of combining transvaginal contrast-enhanced ultrasonography with serum human epididymisprotein-4 and the resistance index for early-stage epithelial ovarian cancer.

Authors:  Wu Meng; Wang Ying; Zheng Qichao; Li Ping; Tang Jie
Journal:  Saudi Med J       Date:  2017-06       Impact factor: 1.484

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.